Patients on antihypertensive medications who still struggle with high blood pressure now have a new treatment option, following the U.S. FDA’s approval of Astrazeneca plc’s baxdrostat. Branded ...
Year-to-date money raised in public, private and other financings of biopharma companies.
Med-tech M&A value through the first four months of 2026 reached $62.01 billion, the highest total for the period since 2022’s $73.58 billion and a dramatic step up from 2025’s $20.03 billion and 2024 ...
On Sunday, May 17th, 2026, the World Health Organization classified the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo (DRC) as a public health emergency of international ...
On the heels of the ouster of Marty Makary as the U.S. FDA commissioner and the serial leadership vacancies at the CDC and the FDA’s drugs and biologics centers, the government’s adherence to science ...
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Psyence.
It looks like the end of the road for many of the court challenges to the Inflation Reduction Act’s (IRA) provision requiring ...
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements bracketing the weekend. On May 15, 2026, ...
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more ...
The number of cases of hantavirus infection has risen from eight to 11, following the repatriation of passengers from the ...
Sonomind SAS raised €20 million (US$23 million) in a series A funding round for its ultrasound-based neuromodulation ...
The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results